{"title":"Diabetes mellitus and long-time outcomes of autovenous femoro-popliteal bypass","authors":"A. Artemova, M. Chernyavskiy","doi":"10.14341/dm12858","DOIUrl":null,"url":null,"abstract":"BACKGROUND: the effect of diabetes mellitus on the long-term patency of autovenous femoro-popliteal bypass has not been definitively determined AIM: to determine the effect of diabetes mellitus on the long-term outcomes of autovenous femoral-popliteal bypass.MATERIALS AND METHODS: the results of treatment of 648 patients who underwent autovenous femoral-popliteal bypass were analyzed. The patients were divided into 2 clinical groups: the first group included 367 patients with diabetes mellitus, the second — 281 patients without the named disease. The groups did not differ significantly in the incidence of concomitant pathology.RESULTS: occlusion of the autovenous conduit within a 5-year period after surgical treatment was observed in 218 patients of the first group (59.4%) and 72 patients of the second group (25.6%) (p <0.01, χ2 = 39.05, RR = 1.78; CI = 1.53–2.12). The average service life of the autovenous femoral-popliteal bypass was 63.49 months in patients of the first group, and 107.46 months in the second. The decompensated course of diabetes mellitus was observed in 203 patients (55.2%). Among patients with decompensated diabetes mellitus, occlusion of the autovenous femoral-popliteal bypass was observed in 95 patients (46.8%), in 104 patients the autovenous conduit was passable (51.2%; p = 0.449, χ2 = 0.57). Decompensated course of diabetes mellitus may contribute to a decrease in the service life of autovenous femoro-popliteal bypass.CONCLUSION: the presence of diabetes mellitus, and especially its decompensated course, can negatively affect the patency of autovenous femoro-popliteal bypass in the long term.","PeriodicalId":11327,"journal":{"name":"Diabetes Mellitus","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Mellitus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/dm12858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND: the effect of diabetes mellitus on the long-term patency of autovenous femoro-popliteal bypass has not been definitively determined AIM: to determine the effect of diabetes mellitus on the long-term outcomes of autovenous femoral-popliteal bypass.MATERIALS AND METHODS: the results of treatment of 648 patients who underwent autovenous femoral-popliteal bypass were analyzed. The patients were divided into 2 clinical groups: the first group included 367 patients with diabetes mellitus, the second — 281 patients without the named disease. The groups did not differ significantly in the incidence of concomitant pathology.RESULTS: occlusion of the autovenous conduit within a 5-year period after surgical treatment was observed in 218 patients of the first group (59.4%) and 72 patients of the second group (25.6%) (p <0.01, χ2 = 39.05, RR = 1.78; CI = 1.53–2.12). The average service life of the autovenous femoral-popliteal bypass was 63.49 months in patients of the first group, and 107.46 months in the second. The decompensated course of diabetes mellitus was observed in 203 patients (55.2%). Among patients with decompensated diabetes mellitus, occlusion of the autovenous femoral-popliteal bypass was observed in 95 patients (46.8%), in 104 patients the autovenous conduit was passable (51.2%; p = 0.449, χ2 = 0.57). Decompensated course of diabetes mellitus may contribute to a decrease in the service life of autovenous femoro-popliteal bypass.CONCLUSION: the presence of diabetes mellitus, and especially its decompensated course, can negatively affect the patency of autovenous femoro-popliteal bypass in the long term.